Lupin Launches Ipratropium Nasal Spray in US—Taps Into $63 Mn Allergy Relief Market

Lupin Ltd has announced the US launch of its Ipratropium Bromide Nasal Spray, a generic version of Atrovent Nasal Spray 0.03%, targeting the treatment of rhinorrhea (runny nose) associated with allergic and non-allergic perennial rhinitis. The product is now available across US pharmacies and is manufactured at Lupin’s Goa facility.

 

According to IQVIA MAT data, the annual US sales for Ipratropium Bromide Nasal Solution are estimated at $63 million, making this a strategic addition to Lupin’s respiratory portfolio. The spray delivers 21 mcg per dose and is typically prescribed for patients aged 6 years and older.

 

This launch strengthens Lupin’s position in the nasal antihistamines and decongestants segment, following recent approvals for other respiratory and ophthalmic products. The company continues to expand its US generics footprint, with over 170 ANDA approvals to date.

 

Key Highlights:

Source: Reuters – Lupin Launches Ipratropium Nasal Spray in US